A phase 2 randomized, double-blinded (BMS-562247 [apixaban] and enoxaparin), active-controlled (enoxaparin and warfarin), parallel-arm, dose-response study of the oral factor Xa inhibitor BMS-562247 in subjects undergoing elective total knee replacement surgery

Trial Profile

A phase 2 randomized, double-blinded (BMS-562247 [apixaban] and enoxaparin), active-controlled (enoxaparin and warfarin), parallel-arm, dose-response study of the oral factor Xa inhibitor BMS-562247 in subjects undergoing elective total knee replacement surgery

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs Apixaban; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms APROPOS
  • Most Recent Events

    • 07 Nov 2012 Planned number of patients changed from 1202 to 1666 as reported by European Clinical Trials Database.
    • 17 Nov 2008 Last checked against ClinicalTrials.gov record.
    • 17 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top